When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation. We form flexible and collaborative partnerships with life science companies to shape the future of real world evidence.
Market of current oncologics and decisions to drive future therapeutic areas.
Read Customer Case Study:
Drug development and build real world comparator arms.
Read Customer Case Study:
New ways of thinking about how trials are designed.
Read Customer Case Study:
Records sourced from tertiary referral centers capture complex and advanced cancers with rigorous EMR documentation and genomic profiling capabilities.
Technology enabled human abstraction allows for nuances in unstructured data to be captured by medical professionals.
Solution oriented agility enables rapid assessment and implementation of augmentation requests.
COTAs standard level dataset goes deeper than traditional sources, capturing the clinical information that is most valuable to life sciences.
Clinicogenomics data
can be added to Focus
Find answers to the most common questions about Cotas services for life sciences.
COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.
COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.
We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.
How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in […]
…
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to leveraging real-world […]
…
Cancer comes in many forms, including hematologic malignancies that originate in blood-forming tissues or in the cells of the immune system, and solid tumors that form as abnormal masses of tissue and are named for the type of cells and classified by the organ or biologic structure from which they originate. Hematologic cancers, such as […]
…Interested in learning more about how we can transform cancer care together?
